List of largest biomedical companies by revenue

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

The following is a list of the top independent pharmaceutical, biotechnology and medical companies ranked by their revenue generated ($10 billion) in the respective financial year, it does not include biotechnology companies that are now owned by, or part of, larger pharmaceutical groups.

The change is the companies relative position in this list, compared to their relative position in the prior year; i.e., an increase would be moving closer to rank 1 and vice versa. Green cells indicate years where revenue increased compared to the previous year, red cells indicate those years where there has been a decrease.

Top pharmaceutical companies with revenue greater than $10 billion[edit]

Rank Chg Company 2019
USD billions
2018
USD billions
2017
USD billions
2016
USD billions
2015
USD billions
2014
USD billions
2013
USD billions
2012
USD billions
2011
USD billions
1 Steady United States Johnson & Johnson
NYSEJNJ
61.37 Q3[1] 81.60[2] 76.50[3] 71.89[4] 70.10[5] 74.30[6] 71.31[7] 67.20[8] 65.00[9]
2 Steady Switzerland Roche
SIXROG
46.29 Q3[10] 56.86[11] 57.37[12] 50.11[13] 47.70[14] 49.86[15] 48.53[16] 47.80[17] 45.21[18]
3 Steady United States Pfizer
NYSEPFE
39.06 Q3[19] 53.60[20] 52.54[21] 52.82[22] 48.85[23] 49.61[24] 51.58[25] 58.99[26] 65.26[27]
4 Steady Switzerland Novartis
NYSENVS
35.04 Q3[28] 51.90[29] 49.11[30] 48.52[31] 49.41[32] 58.00[33] 57.36[34] 56.67[35] 58.57[36]
5 Increase 4 Germany Bayer
FWBBAYN
38.24 Q3[37] 45.06[38] 37.94[39] 25.27[40] 24.09[41] 25.47[42] 24.17[43] 24.30[44] 23.11[45]
6 Steady United Kingdom GlaxoSmithKline
LSEGSK
32.22 Q3[46] 43.14[47] 42.05[48] 34.79[49] 29.84[50] 37.96[51] 41.61[52] 39.93[53] 41.39[54]
7 Steady United States Merck & Co.
NYSEMRK
34.98 Q3[55] 42.30[56] 40.10[57] 39.80[58] 39.50[59] 42.24[60] 44.03[61] 47.27[62] 48.05[63]
8 Decrease 3 France Sanofi
NYSESNY
29.57 Q3[64] 39.07[65] 42.91[66] 36.57[67] 36.73[68] 43.07[69] 42.08[70] 46.41[71] 44.34[72]
9 Increase 1 United States AbbVie
NYSEABBV
24.56 Q3[73] 32.75[74] 28.22[75] 25.56[76] 22.82[77] 19.96[78] 18.79[79]
10 Steady United States Abbott Laboratories
NASDAQABT
23.62 Q3[80] 30.60[81] 27.39[82] 20.85[83] 20.41[84] 20.25[85] 21.85[86] 39.87[87] 38.85[88]
11 Increase 1 United States Eli Lilly & Co
NYSELLY
16.21 Q3[89] 24.56[90] 22.90[91] 21.22[92] 20.00[93] 19.62[94] 23.11[95] 22.60[96] 24.29[97]
12 Increase 1 United States Amgen
NASDAQAMGN
17.17 Q3[98] 23.70[99] 22.80[100] 22.99[101] 21.66[102] 20.06[103] 18.68[104] 17.30[105] 15.58[106]
13 Increase 4 United States Bristol-Myers Squibb
NASDAQBMY
18.32 Q3[107] 22.56[108] 20.80[109] 19.43[110] 16.56[111] 15.88[112] 16.39[113] 17.62[114] 21.24[115]
14 Decrease 3 United States Gilead Sciences
NASDAQGILD
16.32 Q3[116] 22.13[117] 25.70[118] 30.39[118] 32.15[118] 24.47[118] 10.80[118] 9.70[118] 8.39[118]
15 Decrease 1 United Kingdom AstraZeneca
LSEAZN
17.72 Q3[119] 22.09[120] 22.47[121] 23.00[122] 24.71[123] 26.10[124] 25.71[125] 27.97[126] 33.59[127]
16 Decrease 1 Israel/United States Teva Pharmaceutical Industries
NASDAQTEVA
4.30 Q1[128] 18.90[129] 22.40[130] 21.90[131] 20.00[132] 20.27[133] 20.31[134] 18.31[135] 16.12[136]
17 Steady Germany Boehringer Ingelheim
Private
19.48[137] 21.67[138] 17.54[139] 16.41[139] 17.70[139] 18.68[139] 18.89[139] 18.34[139]
18 Steady Japan Takeda Pharmaceutical
TYO: 4502[N 1]
19.10[140] 16.70[141] 15.96 14.93 16.84 17.36 18.91 17.80
19 Steady Germany Merck Group
ETR: MRK
8.66 Q2[142] 16.48[143] 18.70[144] 16.62[145] 14.25[146] 15.29[147] 14.73[144] 14.36[144] 14.31[144]
20 Steady Denmark Novo Nordisk
NYSENVO
13.39 Q3[148] 16.99[149] 18.77[150] 16.61[151] 16.06[152] 15.83[153] 14.88[154] 13.48[155] 11.56[156]
21 Steady Republic of Ireland Allergan plc
NYSEAGN
7.69 Q2[157] 15.78[158] 15.94[159] 14.57[159] 15.07[159] 12.88[160] 8.68[161] 5.91[162] 4.58[163]
22 Steady United States Danaher Corporation
NYSEDHR
15.07 Q3[164] 19.89[165] 18.33[166] 16.88[167] 20.56[168] 19.91[169] 19.12[170] 18.26[171] 16.09[172]
23 Steady United States Celgene
NASDAQCELG
12.95 Q3[173] 15.28[174] 13.00 11.23 9.26 7.67 6.49 5.51 4.84
24 Steady United States Biogen
NASDAQBIIB
10.71 Q3[175] 13.45[176] 12.30[177] 11.40[178] 10.80[179] 9.70[180] 6.90[181] 5.50[182] 5.00[183]
25 Steady Japan Astellas Pharma
TYO: 4503
12.27[184] 12.07 12.63 11.48 10.49 9.25 8.92 8.78
26 Steady United States Labcorp
NYSELH
8.60 Q3[185] 11.33[186] 10.31[186] 9.55[186] 8.51[186] 6.01[186] 5.81[187] 5.67[187] 5.54[187]
27 Steady United States Baxter International
NYSEBAX
8.28 Q3[188] 11.13 [189] 10.56 [190] 10.16 [191] 9.97 [192] 10.72 [193] 14.97 [194] 14.19 [195] 13.89 [196]
28 Steady United States Mylan
NASDAQMYL
5.35 Q2[197] 11.43 [198] 11.91 [199] 11.08 [200] 9.43 [201] 7.72 [202] 6.91 [203] 6.80 [204] 6.13 [205]

See also[edit]

Notes[edit]

  1. ^ Includes the consolidated results of Shire plc from Q4 2018

References[edit]

  1. ^ https://www.biospace.com/article/releases/johnson-and-amp-johnson-reports-2019-third-quarter-results/?s=72
  2. ^ "Johnson & Johnson Reports 2018 Fourth-Quarter Results:". Content Lab - U.S.
  3. ^ "Johnson & Johnson Reports 2017 Fourth-Quarter Results: - Johnson & Johnson". www.jnj.com.
  4. ^ "Johnson & Johnson Reports 2016 Fourth-Quarter Results - Johnson & Johnson". www.jnj.com.
  5. ^ "Johnson & Johnson Reports 2015 Fourth-Quarter Results:".
  6. ^ "Johnson & Johnson Reports 2014 Fourth-Quarter and Full-Year Results - Johnson & Johnson". www.jnj.com.
  7. ^ "Johnson & Johnson Reports 2013 Fourth-Quarter and Full-Year Results - Johnson & Johnson". www.jnj.com.
  8. ^ "Johnson & Johnson Reports 2012 Fourth-Quarter and Full-Year Results:".
  9. ^ "Johnson & Johnson Reports 2011 Fourth-Quarter and Full-Year Results:".
  10. ^ https://www.roche.com/investors/updates/inv-update-2019-10-16.htm
  11. ^ https://www.roche.com/dam/jcr:af865dfd-50fb-458b-9cac-34097db9d3ec/en/ar18e.pdf
  12. ^ "Roche reports good results in 2017". www.roche.com.
  13. ^ https://www.roche.com/dam/jcr:ee2f197f-5487-4629-9e28-66b77c9cbbab/en/ar16e.pdf
  14. ^ https://www.roche.com/dam/jcr:9b36e11d-495c-42f5-b757-e80c4e88d793/en/gb15e.pdf
  15. ^ https://www.roche.com/dam/jcr:880b44a1-3fd6-4e66-bf10-f4af1e724d4d/en/gb14e.pdf
  16. ^ https://www.roche.com/dam/jcr:64fd6b2d-1a76-467f-badd-ab94b85b6d70/en/gb13e.pdf
  17. ^ https://www.roche.com/dam/jcr:3e048249-e3ce-4969-a77e-cc90d8f3fa73/en/gb12e.pdf
  18. ^ https://www.roche.com/dam/jcr:52174b39-feab-4210-82f6-9b8786a69ecf/en/gb11e.pdf
  19. ^ https://www.biospace.com/article/releases/pfizer-reports-third-quarter-2019-results/?s=72
  20. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Quarterly/2018/q4/Q4-2018-PFE-Earnings-Release.pdf
  21. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Quarterly/2017/Q4_2017_PFE_Earnings_Release.pdf
  22. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2016/2016-financial-report.pdf
  23. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2015/2015_Pfizer_Financial_Report.pdf
  24. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2014/2014_Pfizer_Financial_Report.pdf
  25. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2013/FinancialReport2013.pdf
  26. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2012/financial2012.pdf
  27. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2011/financial2011.pdf
  28. ^ https://www.novartis.com/sites/www.novartis.com/files/q3-2019-media-release-en.pdf
  29. ^ https://www.novartis.com/sites/www.novartis.com/files/q4-2018-media-release-en.pdf
  30. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2017-en.pdf
  31. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2016-en.pdf
  32. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2015-en.pdf
  33. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2014-en.pdf
  34. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2013-en.pdf
  35. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2012-en.pdf
  36. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2011-en.pdf
  37. ^ https://www.bayer.com/en/quarterly-reports.aspx
  38. ^ "Bayer's Annual Report 2018". www.annualreport2018.bayer.com.
  39. ^ http://www.annualreport2017.bayer.com/servicepages/downloads/files/bayer_ar17_entire.pdf
  40. ^ http://www.annualreport2016.bayer.com/servicepages/downloads/files/bayer_ar16_entire.pdf
  41. ^ http://www.annualreport2015.bayer.com/servicepages/downloads/files/entire_bayer_ar15.pdf
  42. ^ AG, Bayer. "Bayer – Global Home". www.bayer.com.
  43. ^ https://www.bayer.com/en/ar-2013.pdfx
  44. ^ https://www.bayer.com/en/ar-2012.pdfx
  45. ^ https://www.bayer.com/en/ar-2011.pdfx
  46. ^ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-sales-of-94-billion-plus16-aer-plus11-cer-pro-forma-plus6-cerstar/
  47. ^ "GSK delivers sales, earnings and cash flow growth in 2018 - GSK". www.gsk.com.
  48. ^ https://www.gsk.com/media/4629/fy-2017-results-announcement.pdf
  49. ^ https://www.gsk.com/media/3609/annual-report-2016.pdf
  50. ^ https://www.gsk.com/media/2718/gsk-annual-report-2016.pdf
  51. ^ https://www.gsk.com/media/2710/gsk-annual-report-2014-interactive.pdf
  52. ^ https://www.gsk.com/media/2701/annual-report-2013-interactive.pdf
  53. ^ https://www.gsk.com/media/2694/annual-report-2012.pdf
  54. ^ https://www.gsk.com/media/2696/annual-report-2011.pdf
  55. ^ https://www.biospace.com/article/releases/merck-announces-third-quarter-2019-financial-results/?s=72
  56. ^ "Merck Announces Fourth-Quarter and Full-Year 2018 Financial Results". BioSpace.
  57. ^ LaVito, Angelica (2 February 2018). "Merck posts mixed fourth-quarter results as Keytruda sales skyrocket".
  58. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2017/Q4/merck-q4-10k.pdf
  59. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2015/annual/MRK_2015_Form_10-K_FINAL_r879.pdf
  60. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2014/annual/2014-Form-10-K_FINAL_022715.pdf
  61. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2013/annual/MRK_2013_Form_10_K_FINAL_022714.pdf
  62. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2012/annual/MRK_form_10_k_2012.pdf
  63. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2011/annual/form-10-k-2011.pdf
  64. ^ https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/Q3_2019_Results_Press_Release_EN.pdf?la=en&hash=8BF184008D241B7AB03515AE9F73CEB3
  65. ^ https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/press-releases/Q42018results.pdf?la=en&hash=CDCE30350F0C658C000A909535AD9AF636A93560
  66. ^ https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/en/investors/docs/press-releases/Press_release_Q4_FY_2017.pdf
  67. ^ https://en.sanofi.com/Images/49288_20-F_2016.pdf
  68. ^ https://en.sanofi.com/Images/45889_Sanofi_20-F_2015_V2.pdf
  69. ^ https://en.sanofi.com/Images/38473_Sanofi_20-F_2014.pdf
  70. ^ https://en.sanofi.com/Images/35795_20F_SANOFI_2013.pdf
  71. ^ https://en.sanofi.com/Images/31972_20-F_2012_V2.pdf
  72. ^ https://en.sanofi.com/Images/29804_20F_2011.pdf
  73. ^ https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-third-quarter-2019-financial-results
  74. ^ "AbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results - AbbVie News Center". news.abbvie.com.
  75. ^ "Financial Release - AbbVie". investors.abbvie.com.
  76. ^ "Financial Release - AbbVie". investors.abbvie.com.
  77. ^ "Financial Release - AbbVie". investors.abbvie.com.
  78. ^ "Financial Release - AbbVie". investors.abbvie.com.
  79. ^ "Financial Release - AbbVie". investors.abbvie.com.
  80. ^ https://www.biospace.com/article/releases/abbott-reports-third-quarter-2019-results/?s=72
  81. ^ "Abbott Reports 2018 Results and Issues Strong Forecast for 2019". BioSpace.
  82. ^ Abbott. "Abbott Reports Fourth-Quarter 2017 Results". www.prnewswire.com.
  83. ^ Abbott. "Abbott Reports Fourth-Quarter 2016 Results". www.prnewswire.com.
  84. ^ "Abbott Reports Fourth-Quarter 2015 Results".
  85. ^ "Abbott Reports Fourth-Quarter 2014 Results".
  86. ^ Abbott. "Abbott Reports Fourth-Quarter and Full-Year 2013 Results". www.prnewswire.com.
  87. ^ "Abbott Reports Fourth-Quarter and Full-Year 2012 Results".
  88. ^ "Abbott Hosts Conference Call for Fourth-Quarter and Full-Year 2011 Earnings - FiercePharma". www.fiercepharma.com.
  89. ^ https://investor.lilly.com/static-files/3039632a-fb64-4803-b081-31689cbac13a
  90. ^ "Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology". BioSpace.
  91. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x970018/15B962F7-AF5A-4FFA-BE13-42206D3A0820/Q4_2017_PressRelease.pdf
  92. ^ "Lilly Reports Fourth-Quarter and Full-Year 2016 Results (NYSE:LLY)". investor.lilly.com.
  93. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x871993/5BE670A3-2B82-4876-8471-CA6BC3BD49F8/Lilly_Q4_2015_Press_Release.pdf
  94. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x806120/8637C572-31C4-402E-A179-5E107A5366B2/Q414_Lilly_Sales_and_Earnings_Press_Release.pdf
  95. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x721860/2DB60538-94FE-4E96-98D2-DA72CC301EA0/Q413%20Lilly%20Sales%20and%20Earnings%20Press%20Release.pdf
  96. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x631117/85679233-E13C-4FE7-9431-E97EFFDA6D5D/Q412%20Lilly%20Sales%20and%20Earnings%20Press%20Release.pdf
  97. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x538046/24A15621-7850-45EC-8E20-30535C3D9FC9/Q411_Lilly_Sales_and_Earnings_Press_Release.pdf
  98. ^ http://investors.amgen.com/news-releases/news-release-details/amgen-reports-third-quarter-2019-financial-results
  99. ^ "Amgen - Investors - Press Release". investors.amgen.com.
  100. ^ "Amgen Reports Fourth Quarter And Full Year 2017 Financial Results". www.amgen.com.
  101. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjY1NTQ1fENoaWxkSUQ9MzczMzk1fFR5cGU9MQ==&t=1
  102. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjI2OTYzfENoaWxkSUQ9MzI5ODc3fFR5cGU9MQ==&t=1
  103. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTc0NTMzfENoaWxkSUQ9Mjc3NjczfFR5cGU9MQ==&t=1
  104. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTM3Nzc3fENoaWxkSUQ9MjI2ODE2fFR5cGU9MQ==&t=1
  105. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDk5NjQxfENoaWxkSUQ9NTM5NDU4fFR5cGU9MQ==&t=1
  106. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTM0MzEzfENoaWxkSUQ9LTF8VHlwZT0z&t=1
  107. ^ https://s21.q4cdn.com/104148044/files/doc_financials/quarterly_reports/2019/q3/Q32019-Earnings-Release.pdf
  108. ^ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results - BMS Newsroom". news.bms.com.
  109. ^ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results". investors.bms.com.
  110. ^ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results - BMS Newsroom". news.bms.com.
  111. ^ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results - BMS Newsroom". news.bms.com.
  112. ^ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2014 Financial Results - BMS Newsroom". news.bms.com.
  113. ^ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2013 Financial Results - BMS Newsroom". news.bms.com.
  114. ^ https://s21.q4cdn.com/104148044/files/doc_financials/annual_reports/Bristol-Myers-Squibb-2012AR-lr.pdf
  115. ^ https://s21.q4cdn.com/104148044/files/doc_financials/annual_reports/BristolMyersSquibb-2011-AnnualReport.pdf
  116. ^ https://www.biospace.com/article/releases/gilead-sciences-announces-third-quarter-2019-financial-results/?s=72
  117. ^ "Gilead Sciences Announces Fourth Quarter and Full Year 2018 Financial Results". BioSpace.
  118. ^ a b c d e f g "Investor Overview". Gilead Sciences.
  119. ^ https://www.astrazeneca.com/content/dam/az/PDF/2019/q3/Year-to-date_and_Q3_2019_Results_announcement.pdf
  120. ^ https://www.astrazeneca.com/content/dam/az/PDF/2018/full-year/Full-Year_2018_Results_announcement.pdf
  121. ^ https://www.astrazeneca.com/content/dam/az/PDF/2017/Full-Year/Full-Year%202017%20Results%20announcement%20.pdf
  122. ^ https://www.astrazeneca.com/content/dam/az/PDF/Full_year_and_q4_2016_results/Full_Year_and_Q4_2016_Results_announcement.pdf
  123. ^ "Full-Year and Q4 2015 Results". www.astrazeneca.com.
  124. ^ "AstraZeneca PLC fourth quarter and full year results 2014". www.astrazeneca.com.
  125. ^ "AstraZeneca PLC fourth quarter and full year results 2013 - AstraZeneca". www.astrazeneca.com.
  126. ^ "AstraZeneca PLC Fourth quarter and full year results 2012". www.astrazeneca.com.
  127. ^ "AstraZeneca PLC Fourth quarter and full year results 2011". www.astrazeneca.com.
  128. ^ https://s22.q4cdn.com/366566841/files/doc_financials/2019/quarterly/Q1-2019-PR-tables.pdf
  129. ^ https://s22.q4cdn.com/366566841/files/doc_financials/2018/q4/PR_Q4.2018_Final_Feb.13.2019.pdf
  130. ^ "Teva Reports 2017 Full Year and Fourth Quarter Financial Results".
  131. ^ http://www.tevapharm.com/news/teva_reports_full_year_and_fourth_quarter_2016_financial_results_02_17.aspx
  132. ^ http://www.tevapharm.com/news/teva_reports_full_year_2015_and_fourth_quarter_financial_results_02_16.aspx
  133. ^ "Teva Reports Fourth Quarter and Full Year 2014 Results". www.tevapharm.com.
  134. ^ http://www.tevapharm.com/news/teva_reports_fourth_quarter_and_full_year_2013_results_02_14.aspx
  135. ^ "Teva Reports Fourth Quarter and Full Year 2012 Results". tevapharm.com.
  136. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTI2NDkwfENoaWxkSUQ9LTF8VHlwZT0z&t=1
  137. ^ http://annualreport.boehringer-ingelheim.com/fileadmin/Download-Center/BI_GB_18_en_ohne_Unterschriften.pdf
  138. ^ "Boehringer Ingelheim 2017 Annual Report" (PDF). www.boehringer-ingelheim.com.
  139. ^ a b c d e f "Boehringer Ingelheim total revenue 2007-2017 - Statistic". Statista.
  140. ^ https://www.takeda.com/newsroom/newsreleases/2019/takeda-reports-fy2018-full-year-results-and-issues-fy2019-guidance/
  141. ^ "Takeda reports FY2017 full year results and issues FY2018 guidance". www.takeda.com.
  142. ^ https://www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2019-q2/en/2019-Q2-Press-Release-EN.pdf
  143. ^ "Q4/FY Results of 2018 - News - Merck KGaA, Darmstadt, Germany". www.emdgroup.com.
  144. ^ a b c d "404 page - EMD Group". www.emdgroup.com.
  145. ^ http://ar2016.merckgroup.com/sites/default/files/downloads/en/merck_annual_report_2016.pdf
  146. ^ http://ar2015.emdgroup.com/sites/default/files/downloads/emd/Merck_GB2015_EN.pdf
  147. ^ http://ar2014.merckgroup.com/sites/default/files/downloads/en/Merck_GB2014_EN.pdf
  148. ^ https://www.novonordisk.com/content/dam/Denmark/HQ/investors/irmaterial/quarterly_financial_reports/2019/20191101_Financial%20statement%20Q3%202019.pdf
  149. ^ https://www.novonordisk.com/content/dam/Denmark/HQ/investors/irmaterial/quarterly_financial_reports/2019/20190201_Financial%20statement%20Q4%202018_UK.pdf
  150. ^ "News details". www.novonordisk.com.
  151. ^ https://www.novonordisk.com/content/dam/Denmark/HQ/investors/irmaterial/quarterly_financial_reports/2017/20170202_Financial%20statement_FY%202016_UK.pdf
  152. ^ Transcripts, SA (3 February 2016). "Novo Nordisk's (NVO) CEO Lars Rebien Sorensen on Q4 2015 Results - Earnings Call Transcript".
  153. ^ Transcripts, SA (30 January 2015). "Novo Nordisk's (NVO) CEO Lars Sorensen on Q4 2014 Results - Earnings Call Transcript".
  154. ^ Transcripts, SA (31 January 2014). "Novo Nordisk A/S Management Discusses Q4 2013 Results - Earnings Call Transcript".
  155. ^ Transcripts, SA (31 January 2013). "Novo Nordisk's CEO Discusses Q4 2012 Results - Earnings Call Transcript".
  156. ^ http://www.novonordisk.co.uk/content/dam/Denmark/HQ/Commons/documents/Novo-Nordisk-AR-2011-en.pdf
  157. ^ https://www.allergan.com/investors/quarterly-results
  158. ^ "Allergan Reports Fourth Quarter and Full-Year 2018 Financial Results". BioSpace.
  159. ^ a b c https://www.allergan.com/news/news/thomson-reuters/allergan-reports-solid-finish-to-2017
  160. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTczMDc2fENoaWxkSUQ9Mjc1MzEzfFR5cGU9MQ==&t=1
  161. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTM5MDk2fENoaWxkSUQ9MjI4NjI0fFR5cGU9MQ==&t=1
  162. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTc3MTM2fENoaWxkSUQ9LTF8VHlwZT0z&t=1
  163. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDYwMzczfENoaWxkSUQ9NDg4Mzk1fFR5cGU9MQ==&t=1
  164. ^ https://www.biospace.com/article/releases/danaher-reports-third-quarter-2019-results/?s=72
  165. ^ http://investors.danaher.com/download/Danaher_Annual_Report_2018.pdf
  166. ^ http://investors.danaher.com/download/danaher_2017_annualreport.pdf
  167. ^ http://investors.danaher.com/download/Danaher_2016+Annual+Report.pdf
  168. ^ http://investors.danaher.com/download/2015+Danaher+Annual+Report.pdf
  169. ^ http://investors.danaher.com/download/DHR_AR_2014.pdf
  170. ^ http://investors.danaher.com/download/DHR_AR_2013.pdf
  171. ^ http://investors.danaher.com/download/DHR_AR_2012.pdf
  172. ^ http://investors.danaher.com/download/DHR_AR_2011.pdf
  173. ^ https://s22.q4cdn.com/728481125/files/doc_financials/2019/q3/2019-10-31-Q3-2019-earnings-deck_FINAL.pdf
  174. ^ "Celgene Reports Fourth Quarter and Full Year 2018 Operating and Financial Results". BioSpace.
  175. ^ https://investors.biogen.com/static-files/7863b554-d325-44e8-9c2d-ceace9698781
  176. ^ http://investors.biogen.com/static-files/c0d4fbe2-d4f2-404b-be17-19e770386d6e
  177. ^ "Biogen's Spinraza: Great Launch, Rough Ride". 25 January 2018 – via www.bloomberg.com.
  178. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/Biogen_Annual_Report_2016_on_Form_10K.pdf
  179. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/Biogen_Annual_Report_2015_on_Form_10K.pdf
  180. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/Biogen_2014_Annual_Report_Web.pdf
  181. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/BiogenIdec_AR_2013.pdf
  182. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/BiogenIdec_AR_2012.pdf
  183. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/2011ar.pdf
  184. ^ "Astellas Pharma Inc. Annual Report 2018" (PDF). www.astellas.com.
  185. ^ https://www.biospace.com/article/releases/labcorp-announces-2019-third-quarter-results-and-updates-2019-guidance/?s=72
  186. ^ a b c d e http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDE2OTE0fENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636873221632383468
  187. ^ a b c http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MjI4ODI1fENoaWxkSUQ9LTF8VHlwZT0z&t=1
  188. ^ https://s22.q4cdn.com/911189824/files/doc_presentations/2019/10/Q3-2019-BAX-PRELIMINARY-RESULTS-FINANCIAL-SCHEDULES-(FINAL).pdf
  189. ^ https://s22.q4cdn.com/911189824/files/doc_financials/quarterly/2018/q4/Q4-2018-BAX-FINANCIAL-SCHEDULES-(FINAL).pdf
  190. ^ https://s22.q4cdn.com/911189824/files/doc_financials/quarterly/2018/q4/Q4-2018-BAX-FINANCIAL-SCHEDULES-(FINAL).pdf
  191. ^ https://s22.q4cdn.com/911189824/files/doc_financials/quarterly/2017/q4/Q4-2017-BAX-FINANCIAL-SCHEDULES-(FINAL).pdf
  192. ^ https://s22.q4cdn.com/911189824/files/doc_financials/quarterly/2016/q4/Q4-2016-Financial-Schedules.pdf
  193. ^ https://s22.q4cdn.com/911189824/files/doc_financials/quarterly/2015/q4/Q4-2015-Financial-Schedules.pdf
  194. ^ https://s22.q4cdn.com/911189824/files/doc_financials/quarterly/2014/q4/Q4-2014-FINAL-Financial-Schedules.pdf
  195. ^ https://s22.q4cdn.com/911189824/files/doc_downloads/financial_schedules/2012/Reclassified-Sales-Final.pdf
  196. ^ https://s22.q4cdn.com/911189824/files/doc_downloads/financial_schedules/2012/Reclassified-Sales-Final.pdf
  197. ^ https://www.biospace.com/article/releases/mylan-reports-second-quarter-2019-results/?s=72
  198. ^ http://investor.mylan.com/static-files/ed066de0-8491-4327-a044-9bb136d5b8c3
  199. ^ http://investor.mylan.com/static-files/ed066de0-8491-4327-a044-9bb136d5b8c3
  200. ^ http://investor.mylan.com/static-files/ed066de0-8491-4327-a044-9bb136d5b8c3
  201. ^ http://investor.mylan.com/static-files/ed066de0-8491-4327-a044-9bb136d5b8c3
  202. ^ http://investor.mylan.com/static-files/ed066de0-8491-4327-a044-9bb136d5b8c3
  203. ^ http://investor.mylan.com/static-files/29cc2678-5735-461a-9972-6ac01dfce6c4
  204. ^ http://investor.mylan.com/static-files/29cc2678-5735-461a-9972-6ac01dfce6c4
  205. ^ http://investor.mylan.com/static-files/29cc2678-5735-461a-9972-6ac01dfce6c4

External links[edit]